USV has evolved from a reliable producer of Dosage Forms and APIs to a process-driven and research-focused company with an emerging global base.
The focus on research in protein and peptide production by recombinant and chemical synthesis has yielded excellent results, with most molecules in pre-clinical and clinical stages .
USV has also entered into a license agreement with Biotech Consortium India Ltd. (BCIL) to scale-up, manufacture and market a novel conjugate typhoid vaccine developed by a team of scientists at the All India Institute of Medical Sciences (AIIMS), New Delhi. The project is supported by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India. This project would give USV a foray into the new niche area of vaccines.
| Achievements |
- Robust and scalable processes for production of Biosimilar recombinant proteins and peptides
- Completion of pre-clinical studies of 4 products of which 3 are undergoing Phase III clinicals
- Synthesis of Eptifibatide and Bivalirudin which have been made available in the Indian market.
|
| Capabilities |
| The Biosimilar Research Lab includes |
- Molecular Biology (genetic engineering)
- Microbiology
- Fermentation
- Protein Purification
- Analytical facilities to support the above
- Tissue Culture and Immune assay
- Peptide & Nucleotide
|
| 
